Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Research
Affimed Provides Updated Clinical Data from Phase 1/2 Study from AFM13 Precomplexed Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
Heidelberg, Germany, December 10, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed…
Research
Deepening Response of Bexmarilimab in Combination with SoC in Hematological Malignancies: BEXMAB Study Update
TURKU, FINLAND / BOSTON, MA - December 5, 2022 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company …
News
FDA Approves New Targeted Treatment Option for Certain Forms of Acute Myeloid Leukemia in Adults
The U.S. Food and Drug Administration (FDA) granted approval yesterday to olutasidenib (Rezlidhia™) for the treatment of adults with acute myeloid leu…
Professional Education Webcasts
Applying Genomics and Biomarker Testing in Caring for Patients with Blood Cancer: A Primer for Healthcare Providers
Precision medicine is an emerging approach for prediction of disease risk and disease treatment afforded by the delivery of more precise and efficient…
Research
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
Marseille, France, November 11, 2022 – ImCheck Therapeutics presented today the first patient data from EVICTION-2, a Phase I/II clinical trial evalua…
Research
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
BOSTON, Nov. 29, 2022 - X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit …
Research
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
BERKELEY, CA, Nov. 29, 2022 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, toda…
News
The Leukemia & Lymphoma Society’s Presence at ASH Showcases Progress to Advance Cures and Care for Blood Cancer Patients
At the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13), The Leukemia & Lymphoma Society (LLS) will be presenting new …
Patient Education Webcasts
Cafecito con LLS: Hablemos de los Ensayos Clínicos
Professional Education Webcasts
Blood Cancer 101: The Basics on Disease, Treatment, and the Role of the HCP
This activity is intended for oncology social workers, psychologists, nurses, and other healthcare professionals involved in the care of patients with…
News
The Leukemia & Lymphoma Society Earns a Four-Star Rating From Charity Navigator
The Leukemia & Lymphoma Society is proud to announce that because of its strong financial health and ongoing accountability and transparency, LLS has …
News
LLS Applauds FDA Approval of New Treatment Option for Pediatric Patients with Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) yesterday approved brentuximab vedotin (Adcetris®) in combination with standard dose-intensive chemotherap…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
